167 related articles for article (PubMed ID: 19560213)
1. Effect of TLR3 and TLR7 activation in uterine NK cells from non-obese diabetic (NOD) mice.
Lin Y; Ren L; Wang W; Di J; Zeng S; Saito S
J Reprod Immunol; 2009 Oct; 82(1):12-23. PubMed ID: 19560213
[TBL] [Abstract][Full Text] [Related]
2. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
3. Characterization of natural killer cells in nonobese diabetic/severely compromised immunodeficient mice during pregnancy.
Lin Y; Zhong Y; Saito S; Chen Y; Shen W; Di J; Zeng S
Fertil Steril; 2009 Jun; 91(6):2676-86. PubMed ID: 18410933
[TBL] [Abstract][Full Text] [Related]
4. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
[TBL] [Abstract][Full Text] [Related]
5. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways.
Sawaki J; Tsutsui H; Hayashi N; Yasuda K; Akira S; Tanizawa T; Nakanishi K
Int Immunol; 2007 Mar; 19(3):311-20. PubMed ID: 17289654
[TBL] [Abstract][Full Text] [Related]
6. Activation of cytokine-producing and antitumor activities of natural killer cells and macrophages by engagement of Toll-like and NOD-like receptors.
Qiu F; Maniar A; Diaz MQ; Chapoval AI; Medvedev AE
Innate Immun; 2011 Aug; 17(4):375-87. PubMed ID: 20682587
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 3 agonist enhances IFN-gamma and TNF-alpha production by murine uterine NK cells.
Zhang J; Sun R; Wei H; Wu D; Tian Z
Int Immunopharmacol; 2007 May; 7(5):588-96. PubMed ID: 17386406
[TBL] [Abstract][Full Text] [Related]
8. The synergy in cytokine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages.
Suet Ting Tan R; Lin B; Liu Q; Tucker-Kellogg L; Ho B; Leung BP; Ling Ding J
Immunol Cell Biol; 2013 May; 91(5):377-87. PubMed ID: 23567895
[TBL] [Abstract][Full Text] [Related]
9. APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA.
Schmidt KN; Leung B; Kwong M; Zarember KA; Satyal S; Navas TA; Wang F; Godowski PJ
J Immunol; 2004 Jan; 172(1):138-43. PubMed ID: 14688319
[TBL] [Abstract][Full Text] [Related]
10. Molecular identification and functional expression of porcine Toll-like receptor (TLR) 3 and TLR7.
Sang Y; Yang J; Ross CR; Rowland RR; Blecha F
Vet Immunol Immunopathol; 2008 Sep; 125(1-2):162-7. PubMed ID: 18533275
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of Toll-like receptors in chicken heterophils.
Kogut MH; Iqbal M; He H; Philbin V; Kaiser P; Smith A
Dev Comp Immunol; 2005; 29(9):791-807. PubMed ID: 15936435
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
13. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
14. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages.
Loniewski KJ; Patial S; Parameswaran N
Mol Immunol; 2007 Jul; 44(15):3715-23. PubMed ID: 17507094
[TBL] [Abstract][Full Text] [Related]
16. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
17. CD4
Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ induces aberrant CD49b⁺ NK cell recruitment through regulating CX3CL1: a novel mechanism by which IFN-γ provokes pregnancy failure.
Li ZY; Chao HH; Liu HY; Song ZH; Li LL; Zhang YJ; Yang Y; Peng JP
Cell Death Dis; 2014 Nov; 5(11):e1512. PubMed ID: 25375377
[TBL] [Abstract][Full Text] [Related]
19. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells.
Shojaei H; Oberg HH; Juricke M; Marischen L; Kunz M; Mundhenke C; Gieseler F; Kabelitz D; Wesch D
Cancer Res; 2009 Nov; 69(22):8710-7. PubMed ID: 19887600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
